|
|
Article: Genentech, OSI Begin Phase II With Tarceva For Brain Cancer.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
Marching ahead with their global development plan for Tarceva (erlotinib), Genentech Inc. and OSI Pharmaceuticals Inc. said they have begun a Phase II trial with the drug against malignant glioma, or brain cancer.
"We literally enrolled our first patient this week," said Colleen Sweeney, senior manager of corporate relations for South San Francisco-based Genentech, adding that it's too early to estimate when the trial might finish. The companies might use positive Phase II data in a bid for approval, she said.
"The primary endpoint is overall response rate, and since there is such a medical need, we could take [positive data] to ...
Related newspaper, magazine, and journal articles:
|
|
Article: MEGABIOS, GENEMEDICINE AGREE TO `STRATEGIC MERGER' THAT POOLS ...
BIOWORLD Today;
October 27, 1998 ;
700+ words
... ... percent, or $0.281. McGraw told BioWorld Today the move is one of the few "strategic ... into GeneMedicine," Weintraub told BioWorld Today. "This merger allows us to simplify ... up relatively early," Waldron told BioWorld Today. "This merger announcement is the ...
|
|